Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma

2016 ◽  
Vol 471 (4) ◽  
pp. 596-602 ◽  
Author(s):  
Honglei Luo ◽  
Hong Li ◽  
Zhaoyang Hu ◽  
Hongjin Wu ◽  
Chenglin Liu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Deep Sequencing ◽  
Circulating Tumor Dna ◽  
Noninvasive Diagnosis ◽  
Tumor Dna

scholarly journals Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Tao Liu ◽  
Qianqian Yao ◽  
Hai Jin
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Minimal Residual Disease ◽  
Squamous Cell ◽  
Residual Disease ◽  
Circulating Tumor Dna ◽  
Genetic Alterations ◽  
Tumor Dna ◽  
Minimal Residual

Esophageal squamous cell carcinoma (ESCC) is lethal as tumors are rarely detected at an early stage and have a high recurrence rate. There are no particularly useful biomarkers for the prognostic prediction of ESCC. Circulating tumor DNA (ctDNA) is becoming an important biomarker for non-invasive diagnosis and monitoring tumor prognosis. Here, we aimed to analyze variations in plasma cell-free DNA (cfDNA) amount to search for minimal residual disease (MRD). Plasma and white blood cells (WBCs) of 60 patients were collected before tumor resection and a week after surgery. Tumor specimens were also collected as formalin-fixed paraffin-embedded (FFPE) samples. All samples were extracted to analyze the genetic alterations of 61 genes using capture-based next-generation sequencing (NGS). Tumor variants were detected in 38 patients with ESCC, and the two driver genes with the highest mutation frequency were TP53 and PIK3CA. Of the pre-surgical plasma cfDNA samples, 73.7% of identified variants matched the tissue. In patients who did not receive adjuvant therapy after surgery, postoperative cfDNA-positive patients had shorter overall survival (hazard ratios (HR), 25.8; 95% CI, 2.7–242.6; P = 0.004) and were more likely to relapse than postoperative cfDNA-negative patients (HR, 184.6; 95% CI, 3.6–9576.9; P = 0.01). Detection of ctDNA after surgical tumor excision is associated with tumor relapse and disease-specific survival, and can be used as a prognostic biomarker for MRD detection in ESCC.

scholarly journals Circulating tumor DNA dynamics analysis in a xenograft mouse model with esophageal squamous cell carcinoma

2021 ◽  
Vol 27 (41) ◽  
pp. 7134-7143
Author(s):  
Hiroyuki Terasawa ◽  
Hideaki Kinugasa ◽  
Kazuhiro Nouso ◽  
Shumpei Yamamoto ◽  
Mami Hirai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Mouse Model ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Circulating Tumor Dna ◽  
Dynamics Analysis ◽  
Dna Dynamics ◽  
Xenograft Mouse Model ◽  
Tumor Dna

scholarly journals P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)

2017 ◽  
Vol 12 (1) ◽  
pp. S947-S948
Author(s):  
Vincent Lam ◽  
Hai Tran ◽  
Kimberly Banks ◽  
Waree Rinsurongkawong ◽  
Vassiliki Papadimitrakopoulou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Circulating Tumor Dna ◽  
Genomic Profiling ◽  
Cancer Genes ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document